ArticleJHEP reports : innovation in hepatology2026
Prognostic implications of tumour number in intrahepatic cholangiocarcinoma.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Intrahepatic cholangiocarcinoma (ICC) with multiple liver tumours is staged as T2 disease in the 8 Methods: Patients who were diagnosed with ICC with solitary liver tumours or multiple liver tumours between May 2008 and December 2019 at three tertiary referral centres in Hong Kong, Seoul and Shanghai were enrolled. Kaplan-Meier analyses and multivariable Cox proportional hazards models were used to analyse the association between tumour multiplicity and overall survival (OS). Results: A total of 849 patients were included in the analysis. Among the 563 patients without distant metastasis, 434 (77.1%) and 129 (22.9%) had solitary and multiple liver tumours at baseline, respectively. The median follow-up period was 91.9 months (IQR 69.6-131.5). Median OS for patients with a solitary liver tumour, multiple liver tumours, and distant metastasis was 39.5 months (95% CI 34.4-49.2), 14.8 months (11.4-20.3), and 7.1 months (95% CI 6.1-8.3), respectively (log-rank Conclusions: Tumour multiplicity in ICC is associated with inferior OS compared with solitary liver tumours, particularly in patients with ≥4 tumours. Future ICC staging systems should consider the prognostic significance of tumour number. Impact and implications: Our research provides critical insights into the prognosis of intrahepatic cholangiocarcinoma (ICC) with multiple liver tumours, highlighting the significant impact of tumour multiplicity on survival outcomes. This work addresses the gap in the current staging system, which does not adequately reflect the poor prognosis associated with multiple tumours, especially with the presence of ≥4 tumours. Incorporating these insights into clinical practice could aid in treatment decision-making, risk stratification, and potentially improve patient care and outcomes in ICC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.